



Current Agreements

Dealdoc

Second amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain

AstraZeneca
Pozen

Oct 01 2008

Second amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain

Companies:	AstraZeneca Pozen
Announcement date:	Oct 01 2008 Co-development and licensing agreement for Vimovo (naproxen and esomeprazole combination) for pain Amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain
Related contracts:	First amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain Amendment to co-development and licensing agreement for naproxen and esomeprazole combination for pain

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Oct 01 2008
Start date:	Oct 01 2008
Industry sectors:	Bigpharma Pharmaceutical Drug delivery Musculoskeletal » Arthritis » Osteoarthritis
Therapy areas:	Musculoskeletal » Arthritis » Rheumatoid arthritis Musculoskeletal » Symptoms » Bone pain Musculoskeletal » Symptoms » Muscular pain
Technology types:	Drug delivery Small molecules
Deal components:	Co-development Licensing
Stages of development:	Phase III Formulation
Geographic focus:	Worldwide

Financials

Termsheet

Not available.

Press Release

Not available.

Filing Data

Not available.

Contract

AMENDMENT NO. 2 TO THE COLLABORATION AND LICENSE AGREEMENT

This Amendment No. 2 to the Collaboration and License Agreement (this "Amendment No. 2") is made effective as of October 1, 2008 (the "Amendment No. 2 Effective Date") by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina ("POZEN"), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden ("AstraZeneca"). POZEN and AstraZeneca may be referred to herein individually as a "Party," or collectively as the "Parties."

RECITALS

A. POZEN and AstraZeneca entered into that certain Collaboration and License Agreement, dated as of August 1, 2006, and effective as of September 7, 2006 (as amended hereby, the "Agreement").

B. POZEN and AstraZeneca entered into an Amendment No. 1 to the Agreement effective as of September 6, 2007;

C. POZEN and AstraZeneca desire to amend the Agreement.

NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the parties hereto agree to amend the Agreement as follows:

Capitalized terms used herein have the respective meanings assigned to them as defined in this Amendment No. 2. Other capitalized terms not otherwise defined herein have the meaning ascribed thereto in the Agreement.

ARTICLE 1 - AMENDMENTS

1.1 Amendment to Section 3.3.3. Section 3.3.3 of the Agreement is hereby amended and restated to read in its entirety as follows:

"AstraZeneca will pay POZEN within *** (***) days following the receipt *** of the invoice sent as hard copy and also in the form of a pdf file via e-mail for Direct costs and FTE Costs that do not exceed the then current ADA Budget by more than *** percent (**%); provided, that the GPT will approve variances above **% if and to the extent the variances are (a) reasonable in light of prevalent market conditions for similar work and consistent with POZEN's expenditures on Core Development Activities to the extent the activities are comparable, or (b) beyond POZEN's reasonable control."

The parties agree that the amendment to section 3.3.3 set forth above will apply to all invoices outstanding as of the Amendment No. 2 Effective Date.

*** Portion for which confidential treatment requested.

- 1 -

1.2 Amendment to Exhibit F (TPP Profile and TPP Studies). Exhibit F of the Agreement as revised and attached to Amendment No. 1 is hereby amended and restated to read in its entirety as set forth in Exhibit F attached hereto:

ARTICLE 2 – REFERENCE TO AND EFFECT ON THE AGREEMENT

2.1 Reference to Agreement. Upon and after the effectiveness of this Amendment No. 2, each reference in the Agreement to "this Agreement," "hereunder," "hereof" or words of like import referring to the Agreement shall mean and be a reference to the Agreement as modified and amended by Amendment No. 1 and this Amendment No. 2.

2.2 Effectiveness of Agreement. The Amendment No. 2 set forth above shall not be effective until execution and delivery of this Amendment No. 2 by both parties. Except as specifically amended above, the Agreement, as amended, is and shall continue to be in full force and effect and is hereby in all respects ratified and confirmed and shall constitute the legal, valid, binding and enforceable obligations of the parties.

2.3 No Waiver. The execution, delivery and effectiveness of this Amendment No. 2 shall not operate as a waiver of any right, power or remedy of either Party under the Agreement, no constitute a waiver of any provision of the Agreement.

ARTICLE 3 - MISCELLANEOUS

3.1 Governing Law; Dispute Resolution. Section 15.4 of the Agreement governs any dispute arising out of or related to this Amendment No. 2.

